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Abstract
Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging menin-
giomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of 
meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically 
resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation 
therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence pri-
marily stemming from retrospective, single-institution reports. Two of the first cooperative group studies (RTOG 0539 
and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown 
promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. 
However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel 
molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.
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Meningiomas are primarily a neurosurgical disease and 
while the majority of tumors are histologically classified 
as “benign,” the clinical course and impact on patients and 
caregivers can be far from benign. First-line treatments 
include surgery, followed by (in selected cases) fractionated 
radiation therapy (RT) or stereotactic radiosurgery (SRS). 
The indications for treatment should be individualized and 
take into consideration factors such as age, comorbidity, life 
expectancy, patient preference, histologic grade, molecular 
factors, tumor location, and extent of resection.
We increasingly recognize that like other recognized neo-
plastic entities, meningioma comprises a spectrum of dis-
ease with marked variation in tumor biology and clinical 
outcomes. A patient with a small, heavily calcified, asymp-
tomatic incidental meningioma is unlikely to require any 
treatment and indeed may not need long-term monitoring.1,2 
In contrast, a patient with a large symptomatic meningioma 
causing epilepsy or neurological deficit requires surgery 
and, depending on the histopathology grade or extent of 
resection, may also need adjuvant RT or SRS. While there 
are no approved medical therapies for meningioma, sys-
temic therapy is largely used in higher-grade tumors as a last 
resort once all surgery and RT options have been exhausted, 
but typically results in only modest efficacy.3,4
While the majority of meningiomas have excellent long-
term control rates, due to their slow growth, clinical ser-
ies with follow-up in the range of 5–10 years carry the risk 
of underreporting late meningioma recurrences that can 
occur decades after primary treatment.5 For patients with 
clinically aggressive meningiomas with early and multiple 
recurrences, multimodality treatment is required, com-
bining surgery and radiation therapy, and in select cases 
chemotherapy or experimental clinical trials for treatment-
refractory tumors. Although support for these approaches 
is rooted in historical series of cases, several advance-
ments that deserve attention have been made in each 
therapeutic modality. This review will address advances in 
each of these modalities as well as the evidence support-
ing their use, and will provide general recommendations 
for advancing the treatment of patients with meningiomas.
Surgery for the Treatment of 
Intracranial Meningioma
Surgery is the primary treatment for the majority of patients 
with symptomatic and enlarging meningiomas.2 Surgery 
not only removes the tumor to relieve mass effect, but also 
can rapidly improve neurological function and control sei-
zures.6,7 The surgical gold standard for meningioma is com-
plete resection of tumor and any involved dura or bone, 
while minimizing neurological morbidity in order to achieve 
long-term local control or cure. Moreover, surgery also pro-
vides tissue for histological diagnosis of meningioma type 
and grade8 and for translational research.9–14 While there is 
no standardized method for surgical sampling of meningi-
oma, it is incumbent on surgeons to ensure that adequate 
tissue is provided and any evidence of macroscopic brain 
invasion is reported to the pathologist to ensure accurate 
grading, especially in the light of the revised version of the 
World Health Organization (WHO) grading system, where 
brain invasion alone is sufficient for diagnosis of WHO 
grade II.8,15 Moreover, adequate tissue will allow for the 
possibility of future molecular analysis, if needed.
Evolution of Surgery for Meningioma
Evidence for the effectiveness of surgery as monotherapy 
for meningioma is largely derived from single institutional 
case series. Reports of neurosurgical outcomes were his-
torically limited to tumor recurrence, complication, and 
mortality rates. Recognizing that so called benign menin-
giomas regrew despite apparently satisfactory surgery, in 
1957 Simpson described a classification system to define 
the risk of recurrence following surgery alone based on 
the surgeon’s intraoperative assessment of the extent of 
resection (Table 1).16 Recognizing that extent of resection 
was important to reduce the risk of recurrence, the neuro-
surgery community strove for new approaches to achieve 
complete resection. These included new technologies 
such as the operating microscope,17 micro-instruments, 
and cavitational ultrasonic aspirators, and new surgical 
techniques such as approaches to the skull base,18 venous 
sinus reconstruction,19 and in situ cranioplasty for skull 
vault meningiomas.20 These advances heralded an era of 
radical surgical resection, sometimes at the expense of 
neurological function. However, with subsequent improve-
ments in neurosurgical care and recognition that quality of 
life is an important patient outcome, neurosurgeons cur-
rently aim for maximum safe resection with low morbidity 
and preservation of neurological function.21,22
Technical Considerations in Meningioma Surgery
Meningioma surgery can be technically challenging, and 
meticulous presurgical planning with careful attention to 
neurovascular anatomy is essential to maximize success 
and minimize morbidity. Attention to venous anatomy 
will avoid inadvertent injury to cortical veins and intra-
diploic venous drainage that can lead to postoperative 
venous infarction with devastating consequences for the 
patient. Reconstruction of major venous sinuses remains 
a controversial topic, with up to 93% gross total resection 
(GTR) rate, a 3% risk of death,23 and a 21% risk of major 
morbidity.24 An alternative strategy is to leave meningi-
oma invading the sinus that can be monitored or treated 
with adjuvant RT or SRS,25 but it is preferable to attempt to 
remove the tumor completely.
Image guidance is used routinely in cranial neurosurgery to 
position the craniotomy and allows image fusion of multiple 
datasets that provide information about critical neurovascu-
lar structures or transosseous growth. Intraoperative MRI 
(iMRI) and CT (iCT) can be used to update neuronavigation 
and identify residual tumor,26–28 particularly for hyperostotic 
skull base meningiomas. DOTATATE PET can discriminate 
between meningioma and normal tissues with greater sen-
sitivity than MRI,29 and may be particularly useful for men-
ingioma with intraosseous involvement.30 DOTATATE PET 
imaging may also be used as a predictor of tumor growth 
rate (discussed further in the companion imaging article).31
 Intraoperative imaging can also be used for emerg-
ing approaches such as adaptive hybrid surgery, whereby 
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the surgeon plans to leave a small (deemed unresectable) 
residual that can be treated with postoperative SRS.32 In 
addition, intraoperative neurophysiological monitoring (eg, 
facial nerve and brainstem evoked potentials) may help 
minimize postoperative neurological deficit in critically 
located lesions. In the pursuit of complete resection, studies 
of surgical adjuncts such as 5-aminolevulinic acid (5-ALA) 
fluorescence have shown heterogeneous fluorescence 
within the meningioma as well as nonspecific fluorescence 
in adjacent brain,33 which suggests a limited role, although 
a recent systematic review found that 5-ALA may be more 
useful in higher-grade meningioma.31 Fluorescence-guided 
surgery remains a nonstandard adjunct that needs further 
prospective evaluation. Minimally invasive and endoscopic 
endonasal techniques are being used for resection of anter-
ior skull base meningiomas despite the lack of a direct 
comparison to established open transcranial approaches 
in a prospective trial. A recent systematic review and meta-
analysis reported that endoscopic techniques were not 
superior to open craniotomy and achieved lower rates of 
GTR and higher rates of cerebrospinal fluid leak and vas-
cular injury,34 highlighting the fact that new surgical tech-
niques should be subject to rigorous testing before routine 
adoption into clinical practice.35
In patients with recurrent meningiomas, the surgi-
cal challenges are compounded by scar tissue, and the 
underlying brain is often more friable and susceptible to 
injury. Moreover, practical issues also include the ability 
of the scalp to withstand repetitive surgery to heal appro-
priately. The indications for further surgery include symp-
tomatic meningioma growth and reduction of the tumor 
volume to leave a smaller target for postoperative radi-
ation. Minimally invasive surgical options such as laser 
interstitial thermal therapy—where an image-guided 
fiberoptic laser is used to produce irreversible thermal 
damage to a defined focus that can be monitored in real 
time due to advancements of MRI thermometry—have 
been trialed in one small case series of recurrent menin-
giomas.36 However, the small number of patients treated 
with this modality precludes large conclusions regarding 
its efficacy.36
Extent of Resection and Risk of Recurrence
The Simpson classification16 predates CT and MRI as modali-
ties to assess extent of resection. Despite this, the Simpson 
grade remains the only validated surgical method for 
estimating risk of recurrence and is still relevant in modern 
neurosurgery.37,38 A recent systematic review and meta-anal-
ysis reported that Simpson grade still predicts risk of recur-
rence even when stratified by WHO grade.38 However, the lack 
of standardized reporting of recurrence by Simpson grade 
and by tumor location has resulted in grouping of resection 
categories for the purpose of clinical trials (Table 1).39
Neurosurgical Meningioma Trials
There are no randomized controlled trials comparing sur-
gery with other therapies for meningiomas. Historically, 
this problem has been compounded by the potential lack 
of equipoise in head-to-head comparisons with other local 
treatments. Small meningiomas that could be treated 
with resection or SRS may be an exception to the afore-
mentioned problem with equipoise, but such a trial would 
be difficult to conduct for several reasons. First, patients 
with incidental, asymptomatic meningioma do not need 
active treatment and can be safely monitored. Secondly, 
both symptomatic patients and their physicians may 
have strong preferences for one technique and would 
not want to risk randomization to the alternative. Indeed, 
concern for lack of clinical equipoise and surgeon bias 
against RT were contributory factors in the early closure 
of the European Organisation for Research and Treatment 
of Cancer (EORTC) 26021-22021 phase III trial, which ran-
domized patients following biopsy or subtotal resection 
(STR) to observation versus fractionated RT or SRS.
Radiation for the Treatment of 
Meningiomas
Radiation therapy is the only nonsurgical standard of care 
treatment option for meningiomas.2 However, until recently 
the evidence supporting RT for meningioma was largely lim-
ited to single-institution, retrospective data. Indeed, radio-
therapeutic options for meningioma are diverse, and there 
are no randomized trials comparing different RT modali-
ties. As a result, RT technique is individualized and depends 
on meningioma size, proximity to critical structures, and 
any prior radiation to the same site. Despite these caveats, 
excellent local control has been observed following various 
forms of RT for meningioma, including fractionated external 
beam radiation therapy (EBRT), SRS, and brachytherapy.
Table 1 Simpson grades of resection and corresponding EORTC/RTOG definitions of extent of resection16,39
WHO Grade Definition Extent of Resection 
I Gross total resection of tumor, dural attachment, and abnormal bone GTR
II Gross total resection of tumor, coagulation of dural attachment GTR
III Gross total resection of tumor without resection or coagulation of dural attachments,  
or extradural extensions (eg, invaded or hyperostotic bone)
GTR
IV Partial resection of tumor STR
V Biopsy of tumor STR
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Evolution of the Role of Radiation Therapy for 
Meningioma
In the 1950s, Simpson initially proposed that EBRT could 
be considered after an STR.16 However, by the 1960s, sev-
eral investigators reported infrequent tumor shrinkage 
following RT, and in conjunction with concerns for radia-
tion-induced meningioma and late toxicity, it was unclear 
if RT had any role for patients with meningioma.40 Then in 
the 1970s and 1980s, retrospective series with long-term 
follow-up emerged and concluded that EBRT improved 
local control for incompletely resected and recurrent men-
ingiomas.41–43 Furthermore, in the 1990s and early 2000s, 
several reports found similarly efficacious tumor control 
with primary EBRT for upfront treatment.44–47
Evolution of Radiation Therapy Technologies
Three-dimensional conformal radiation therapy
In the early 1990s, 3-dimensional conformal radiation 
therapy (3D-CRT) became widely adopted as a result of 
important technical advancements in CT and multileaf 
collimators. In 3D-CRT, the radiation field of each incident 
beam is shaped to the projection of the target volume in 
the eye view of the beam. The fluence distribution in the 
plane perpendicular to each incident beam is homoge-
neous so it is generally not possible to “dose-paint” hot or 
cold spots into the target. Three-dimensional CRT remains 
a standard treatment option for meningiomas, although 
newer approaches may be better suited for irregular tar-
gets and/or those that are adjacent to critical structures. 
These newer, highly precise methods to deliver conven-
tionally fractionated radiation are also aptly referred to as 
stereotactic radiation therapy in the literature.
Intensity-modulated radiation therapy and volumetric 
modulated arc therapy
Similar to 3D-CRT, intensity-modulated radiation therapy 
(IMRT) refers to EBRT from discrete beam directions. The 
treatment beam is off as the gantry moves from one angle 
to the next, which is commonly referred to as “step-and-
shoot.” Multileaf collimators allow each beam to be discre-
tized into beamlets and for the fluence distribution in the 
plane perpendicular to each incident beam to be modu-
lated. The goal during optimization is to find the fluence 
maps of all incidence beams that provide the desired dose 
distribution in the patient.
Volumetric modulated arc therapy (VMAT) is an exten-
sion of IMRT where the beam is continuously on while the 
gantry rotates around the patient. By treating over more 
gantry angles in an arc sector rather than being limited to 
a few discrete beam angles, VMAT in principle can provide 
more conformal dose distributions than IMRT and treat-
ment times can be shortened.
Particle therapy
There has been comparatively less experience with par-
ticle therapies than photon-based therapies, such as 
3D-CRT, IMRT, and VMAT, due to widespread availabil-
ity of the latter. However, the number of treatment cent-
ers offering proton or carbon ion therapies worldwide has 
increased significantly in recent years. In principle, irradiat-
ing meningiomas with heavy particles rather than photons 
can potentially reduce late toxicities in long-term survivors 
by lowering scatter doses to adjacent normal tissues.48 In 
practice, particle therapy remains investigational and is the 
subject of several ongoing prospective trials. For instance, 
UPCC 24309 (NCT01117844) is a feasibility/phase II study 
of proton radiation for WHO grades I–III meningiomas 
and hemangiopericytomas. Furthermore, a combined 
phase I/II study at Massachusetts General Hospital and MD 
Anderson Cancer Center (NCT02693990) is studying dose 
escalation with proton therapy for atypical meningiomas 
following STR and anaplastic meningiomas following any 
extent of resection. With recent advancements in proton 
therapy intensity modulation, it is possible that heavy par-
ticles may improve outcomes, such as for meningiomas 
near the pituitary gland.
Radiation Target Delineation and Dose 
Prescriptions
Meningiomas are generally homogeneously enhancing, 
extra-axial tumors with hypervascular trailing enhance-
ments from the margins called dural tails. Dural tails are 
typically composed of benign, hypervascular tissue and 
unless they contain suspicious nodular enhancement, they 
do not need to be included in the radiation target. WHO 
grade I  and radiographically defined (presumed grade 
I) meningiomas are commonly treated to a total dose of 
50–54 Gy with a 0–5 mm clinical target volume (CTV) mar-
gin. Grade I meningiomas are not thought to be infiltrative, 
and surrounding hyperintensity is more likely to repre-
sent edema, which should not be included in the gross 
tumor volume (GTV). In contrast, WHO grade II (atypical) 
and grade III (anaplastic) meningiomas are commonly 
treated to 59.4–60 Gy with 10–20 mm GTV to CTV aniso-
tropic expansion that respects anatomic barriers to tumor 
growth, such as the skull. However, hyperostosis or direct 
bone invasion should be included in the GTV. An additional 
margin of 3–5 mm is generally used to create a planning 
target volume from the CTV for all meningiomas, depend-
ing on image-guidance method and reproducibility of the 
treatment setup.
Radiation Therapy Outcomes
Several retrospective studies have reported excellent out-
comes of EBRT as adjuvant therapy after STR of WHO grade 
I  or radiographically defined meningiomas. Furthermore, 
favorable outcomes of EBRT as definitive therapy have been 
reported for patients with meningiomas that are not amen-
able to surgery or are diagnosed in patients who are med-
ically inoperable or elect radiation over surgery. Reported 
outcomes can vary depending on the treatment era, tumor 
characteristics, and clinical scenario but overall are support-
ive of current treatment paradigms with EBRT. In an excel-
lent review, these studies are summarized by Rogers et al.4
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Radiation therapy following subtotal resection
The rate of meningioma recurrence following STR is 
higher than with a GTR. Following a GTR, defined as 
Simpson grades I–III, 5-, 10-, and 15-year recurrence rates 
are 7%, 20%, and 32%, respectively.43 In contrast, the rate 
of local recurrence with STR at 5 years is 47%.41 Several 
retrospective studies have found high rates of local con-
trol in patients treated with EBRT following STR. In that 
regard, 5- and 10-year rates of progression of less than 10% 
have been observed and local control rates have trended 
upward since the 1980s, suggesting that improvements in 
patient stratification, and perhaps EBRT techniques, have 
improved outcomes.49–51
Primary external beam radiation therapy
Retrospective studies of primary EBRT for meningioma 
consist of patients and tumors that are inherently different 
than those selected for surgical monotherapy or observa-
tion. For instance, primary EBRT is useful for certain tumor 
locations where GTR is not possible without causing sig-
nificant morbidity to the patient, such as optic nerve sheath 
meningioma. For example, in a series of 64 patients with 
optic nerve sheath meningiomas, 14 (22%) were treated 
with EBRT alone (40–55 Gy) with no failures and 86% of 
these patients had improved or stable vision at a median 
follow-up of 8.3 years.52 In another series, of 101 patients 
with presumed WHO grade I  skull base meningiomas 
treated with EBRT alone (65%) or after STR (35%), 5-year 
local control was 95% for all patients at a median follow-up 
of 5 years.53
External beam radiation therapy following resection of 
atypical or anaplastic meningioma
High-grade tumors constitute less than one quarter of 
meningiomas, and thus their natural histories and optimal 
treatment paradigms are less clear. Some studies found 
similar outcomes between atypical and anaplastic menin-
giomas,54,55 while others have found significantly higher 
rates of failure in the latter.56,57 The efficacy of adjuvant 
EBRT following the resection of high-grade meningiomas 
is the subject of 2 prospective studies that have closed to 
accrual: Radiation Therapy Oncology Group (RTOG) 0539 
(NCT00895622) and EORTC 22042 (NCT00626730). The 
initial clinical outcomes for the intermediate-risk group 
from RTOG 0539 were recently reported, consisting of 
48 evaluable patients with newly diagnosed, completely 
resected WHO grade II tumors or recurrent WHO grade 
I tumors irrespective of extent of resection. With a median 
follow-up time of 3.7  years, 3-year progression-free sur-
vival (PFS) was 94% following 3D-CRT or IMRT, 54 Gy in 
30 fractions.58 Two additional phase III randomized con-
trolled trials remain open for accrual: Neuro-Oncology 
Research Group (NRG) BN-003 (http://clinicaltrials.gov/ct2/
show/NCT03180268) and the Radiation versus Observation 
following surgical resection of Atypical Meningioma 
(ROAM)/EORTC 1308 trial (http://roam-trial.org.uk; 
ISRCTN71502099), both of which compare surgery plus 
adjuvant RT with surgery alone in grade II meningioma 
status post GTR.59 As discussed below, molecular features 
have largely yet to be incorporated into clinical trials of 
surgery or radiation for meningiomas. Thus, secondary 
subset analyses may be required to identify subgroups of 
patients who derive the most benefit for adjuvant interven-
tions. With respect to the inclusion criteria of NRG BN-003 
and ROAM/EORTC 1308, an MIB-1 labeling index >7% iden-
tifies a subpopulation of grade II meningiomas at high risk 
for local recurrence after GTR, and therefore may benefit 
most from adjuvant radiation.60,61
Stereotactic Radiosurgery
SRS refers to higher dose per fraction RT that is delivered 
with extremely precise 3D localization systems, typically 
within a single session. Although variable among centers, 
single fraction SRS is generally considered feasible for 
tumors less than 3–4 cm in diameter with at least 2 mm 
separation from critical normal structures such as the 
optic nerves and chiasm to allow for sharp dose gradients 
(Fig. 2). Similar to studies with primary EBRT, retrospect-
ive series with Gamma Knife, robotic, and linear acceler-
ator–based SRS have generally been found to prevent the 
growth of grade I  meningiomas.62–66 Even though most 
meningiomas do not shrink significantly after treatment, 
symptomatic improvement can occur after both EBRT 
and SRS.
Fractionated Stereotactic Radiosurgery
Meningiomas can be challenging targets for radiosurgery 
because some tumors, particularly those involving the 
skull base, have irregular contours and indistinct margins. 
Even with sufficient distance from critical normal struc-
tures, it may not be feasible to complete a single-session 
treatment in a reasonable amount of time. Ablative doses 
of RT in 2 to 5 treatments have several synonyms in the lit-
erature: fractionated SRS, stereotactic body RT, and stereo-
tactic ablative RT.
Stereotactic Radiosurgery and Fractionated 
Stereotactic Radiosurgery Outcomes
The largest published series of grade I  and radiograph-
ically defined meningiomas treated with Gamma Knife 
radiosurgery reported outcomes of 5300 lesions with 
median tumor volume of 4.8  cm3 in 4656 patients who 
were treated at 15 participating centers to a median mar-
ginal dose of 14 Gy.67 With a median imaging follow-up of 
5.3 years, the 5- and 10-year PFS rates were 95% and 89%, 
respectively. Similarly, in a single institution series with 
median tumor volume of 2.5 cm3 and median prescription 
dose of 15 Gy, 5-year PFS rates of presumed benign (97%) 
and pathologically confirmed WHO grade I (87%) meningi-
omas were excellent following Gamma Knife SRS but were 
suboptimal for WHO grades II (56%) and III (47%) tumors.68 
Furthermore, larger tumor volume (≥10 cm3) was associ-
ated with significantly worse PFS. There have been fewer 
reports describing the outcomes for fractionated SRS for 
tumors that are not amenable to SRS. In a series of 199 
patients with benign or presumed benign meningiomas, 63 
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(32%) were not deemed to be candidates for single-session 
SRS due to the presence of lesions larger than 13.5  cm3 
and/or location within 3 mm of the optic pathways.69 The 
median tumor volume was 7.5 cm3 and prescription doses 
ranging 11–25 Gy were delivered between 2 and 5 daily 
fractions. With a median follow-up of 2.5 years, 5-year PFS 
was 94%, with 7 patients (3.5%) experiencing neurologic 
deterioration. Irrespective of the number of fractions, SRS 
for meningioma is typically well tolerated, with minimal 
toxicity that is often limited to transient fatigue.
Brachytherapy
There are limited options for patients with recurrent atyp-
ical or anaplastic meningiomas after prior radiation ther-
apy to the same site. Repeat surgery alone provides poor 
local control, the operative bed is often too large for SRS, 
and the benefit of systemic therapy is still being investi-
gated. Re-resection followed by permanent-seed low-
dose-rate brachytherapy is a viable salvage treatment 
option in this patient population with very limited options, 
but relatively high complication rates have been observed 
in these heavily treated patients. The largest experience 
with I-125 permanent seed implant at the time of re-resec-
tion of atypical or malignant meningiomas is a series con-
sisting of 42 patients, 85% of whom had a history of prior 
radiation therapy, where the median time to progression 
was 11.4  months.70 Overall complication rates were high 
and observed in 17 patients (40%), consisting of radiation 
necrosis (19%), wound breakdown (14%), wound infection 
(7%), and pseudomeningocele (5%).
Radionuclide Therapy
Like brachytherapy, peptide receptor radionuclide therapy 
(PRRT) may be beneficial for pretreated, progressive men-
ingiomas. Somatostatin receptor type IIA (SSTR) is a highly 
specific marker for meningioma cells that is not otherwise 
expressed in the central nervous system,71 with the excep-
tion of the pituitary gland. Thus, positron emission tom-
ography with SSTR ligands like DOTATATE and DOTATOC 
conjugated to the positron-emitter gallium-68 is being investi-
gated for diagnostic purposes.72 In analogy to neuroendocrine 
tumors,73 DOTA-conjugated SSTR ligands linked with the 
ß-emitters lutetium-177 or yttrium-90 are suitable for PRRT,74–76 
and consistently, meningiomas with higher SSTR expression 
are associated with tracer uptake and clinical response.77,78
Systemic Treatments for Meningiomas
Patients with meningiomas in surgically challenging 
areas, such as the skull base, or patients with progres-
sive or recurrent meningiomas after having undergone all 
potential surgical and radiotherapeutic treatment options, 
may benefit from systemic treatment options. However, 
to date, the efficacy of systemic agents has been disap-
pointing. A variety of systemic treatment agents such as 
temozolomide, bevacizumab, somatostatin analogues, 
hydroxyurea, irinotecan, everolimus, vatalanib (PTK787/
ZK-222584), sunitinib, mifepristone, interferon-α, imatinib, 
erlotinib, gefitinib, and the combination of cyclophospha-
mide, doxorubicin, and vincristine have been investigated, 
and response rates have been, for the most part, small 
(Supplementary Table 1). Unfortunately, the interpretation 
of most meningioma trials can be challenging, as many 
studies are small and underpowered and lack control 
arms.3,79,80 A recent review summarized a total of 47 publi-
cations in regard to the outcomes of meningioma patients 
treated with systemic therapies. The weighted average PFS 
rates at 6 months were 29% (95% CI: 20.3%–37.7%) for WHO 
grade I meningiomas and 26% (95% CI: 19.3%–32.7%) for 
WHO grades II/III meningiomas, highlighting the need for 
improved systemic therapies for these patients.79
Chemotherapy
Trabectedin is a chemotherapeutic agent which is rou-
tinely used for advanced sarcoma as well as for ovarian 
cancer.81,82 Trabectedin has shown activity in in vitro stud-
ies of meningioma, yet other than transcriptional interfer-
ence, the mechanism of action of trabectedin is complex 
and not completely understood.83 Based on these results, 
trabectedin is currently the only chemotherapeutic agent 
being investigated in a randomized, multicenter phase II 
trial for patients with recurrent WHO grades II/III meningi-
omas (EORTC-1320-BTG). This trial has recently completed 
accrual and results are expected in the near future.
Molecular Therapy
In recent years, the identification of specific genetic altera-
tions in meningiomas has improved our understanding 
of this brain tumor and has opened up potential targeted 
treatment options for affected patients (Fig. 1 and 2).
In the 1990s, inactivation of the tumor suppressor gene 
neurofibromatosis 2 (NF2), which encodes for the protein 
merlin on chromosome 22 by either mutations or mono-
somy 22, was established as a driver in about 50% of spor-
adic meningiomas.84–87 Merlin plays a role in the activation 
of the mammalian target of rapamycin (mTOR) pathway 
during the pathogenesis of meningioma by negatively reg-
ulating the mTOR complex 1 (mTORC1)88 and by positively 
regulating the kinase activity of mTORC2.89 Consistently, 
overexpression of mTORC1 pathway components has 
been reported in meningiomas, and mTORC1 inhibitors, 
temsirolimus and everolimus, suppress meningioma 
growth in preclinical mouse models.90 A phase II study of 
everolimus in combination with bevacizumab revealed 
stable disease for more than 6 months in 35% of patients 
(Supplementary Table  1).91 Moreover, the dual mTORC1 
and mTORC2 inhibitor vistusertib (AZD2014) revealed 
promising results in preclinical studies in blocking prolif-
eration of meningioma cells.92 AZD2014 is currently under 
evaluation in 2 phase II trials investigating efficacy in 
patients with recurrent WHO grades II and III meningiomas 
(NCT03071874), and in NF2 patients with progressive or 
symptomatic meningiomas (NCT02831257).
Focal adhesion kinase (FAK) inhibition may be another 
promising avenue in NF2-altered tumors. In other 
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Fig. 1 Potential signaling pathways that can be targeted in meningiomas (A, figure modified with permission from Preusser, Brastianos et al 
Nature Reviews Neurology 2018126). (B) Human tumor samples with mutations in SMO and AKT1 are predominantly meningothelial, whereas NF2 
mutated tumors are fibroblastic and/or transitional. Immunohistochemistry demonstrates activation of the Hedgehog signaling pathway with 
GAB1 positivity and the Akt/PI3K pathway with STMN1 positivity (figure modified with permission from Brastianos et al. Nature Genetics 2013127).
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NF2-mutant tumors such as malignant pleural meso-
thelioma and serous ovarian carcinoma, cells which lack 
expression of merlin have been shown to be sensitive to 
FAK inhibition in in vitro and in vivo studies.93,94 The role 
of FAK inhibitors in NF2-altered meningiomas is currently 
being investigated in a national Alliance-sponsored phase 
II trial (NCT02523014/A071401).
Anti-angiogenic inhibitors have also been investigated in 
meningiomas, with limited demonstrable efficacy. In retro-
spective studies of recurrent or progressive meningiomas, 
bevacizumab has some antineoplastic activity; however, 
these results need to be further validated in randomized 
controlled trials.95,96 In prospective studies, other anti-angi-
ogenic agents, vatalanib and sunitinib, have shown limited 
efficacy, with response rates of 0% and 6%, respectively 
(Supplementary Table 1).97,98
With the advent of massively parallel sequencing 
technologies, strides have been made that increase our 
understanding of the genomic landscape of meningi-
omas. Whole exome and whole genome sequencing have 
revealed that grade I meningiomas display relatively sim-
ple genomes compared with other brain tumors in adult 
patients.9 In addition to NF2 inactivation, alterations in 
epigenetic modifiers which have been associated with can-
cer such as KDM5C, KDM6A, and SMARCB1 were found in 
8% of meningiomas.14 Compounds targeting epigenetic 
changes such as inhibitors of histone deacetylase, DNA 
methyltransferase, enhancer of zeste homolog 2 (EZH2), 
and lysine (K)-specific demethylase 1 (KDM1A) are cur-
rently under evaluation in various clinical trials in other 
cancer types.99 Other inhibitors—for example, the selec-
tive KDM5-inhibitor KDOAM-25100—are being evaluated 
in preclinical trials and may warrant further investigation 
in preclinical studies in meningiomas before these com-
pounds are explored in clinical trials. These agents are of 
particular interest for meningioma given the recently dis-
covered prognostic significance of DNA methylation pro-
file, whereby higher levels of DNA methylation in a set of 
stereotypic cytosine-phosphate-guanine sites delineate 
tumors that are more likely to recur.13,101,102
Using next-generation sequencing techniques, recur-
rent oncogenic mutations have been identified in a subset 
of NF2-wildtype grade I meningiomas, such as mutations 
of AKT1 (8–13%), a member of the phosphatidylinositol-3 
Example
Example
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considerations
Follow-up
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External beam radiation therapy Stereotactic radiosurgery
Large (> 3–4 cm)
Contacting optic apparatus
54 Gy at 1.8 Gy per fraction
Small
≥ 2–3 mm from optic apparatus
15 Gy in a single fraction
No margin added to GTV
Gamma knife SRS commonly
prescribes to 50% isodose line for
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accelorater SRS typically treats at
the 80% isodose line
Increase conformality with IMRT or
VMAT
Prescribe to high isodose line to
minimize hot spots to adjacent
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EBRT and SRS generally prevent the growth of benign meningiomas on long-
term follow-up; transient swelling after RT has been observed
Little to no tumor reduction
Symptomatic improvement is commom despite minimal tumor reduction
Fig.  2 Comparisons of external beam radiation therapy (EBRT) and stereotactic radiosurgery (SRS) for the treatment of presumed benign 
meningiomas.
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kinase (PI3K)/Akt/mTOR pathway, and of Smoothened 
(SMO) (3–5%), a member of the Hedgehog (Hh) path-
way.9,10,103 These mutations tend to be mutually exclusive 
with NF2 mutation, suggesting that they represent inde-
pendent biological drivers of the tumor. These mutations 
can have location specificity as well, as the majority of 
meningiomas harboring AKT1 and SMO mutations are 
present in the skull base.104 In particular, SMO mutations 
are enriched in the olfactory groove location.104 Akt inhibi-
tors are showing promising activity in other AKT-mutated 
tumors.105 Inhibitors of the Hh pathway have not been 
tested in meningioma patients to date, but 2 Hh inhibi-
tors (vismodegib and sonidegib) are FDA approved for the 
treatment of patients with basal cell carcinoma, another 
Hh-associated cancer.106 PIK3CA mutations are approxi-
mately as common as AKT1 and SMO mutations in NF2-
wildtype meningiomas, and the majority of these cases are 
similarly enriched in the skull base.107
Because the skull base is a challenging location for surgery 
and radiotherapy, molecular agents targeting the PI3K/Akt/
mTOR and Hh pathways may in the future represent promis-
ing approaches for some meningioma patients with tumors 
in this location. Indeed, a recent case report demonstrated a 
promising response to an Akt inhibitor in a patient with mul-
tiple recurrent intracranial meningiomas despite repeated 
surgical resections, RT, and other systemic agents.108 
Molecular therapy was well tolerated and resulted in a radio-
graphic tumor reduction of up to 12.5%. After one year of 
treatment with AZD5363, the patient had a sustained clinical 
and radiographic response.108 A national Alliance-sponsored 
cooperative group phase II trial in the US is currently evaluat-
ing the efficacy of SMO, AKT1, and FAK inhibitors in patients 
with residual, recurrent, or progressive meningiomas with 
targetable alterations in SMO, AKT1, and NF2, respectively 
(NCT02523014/A071401). This umbrella trial, the first pre-
cision medicine trial to be conducted in meningiomas, has 
co-primary endpoints of PFS and response rate at 6 months.
Other potential genetic driver alterations in NF2-wildtype 
meningiomas include alterations of the tumor suppressor 
genes cyclin-dependent kinase inhibitor 2A (CDKN2A) and 
CDKN2B, especially in atypical and anaplastic meningi-
omas.109 In addition, malignant progression to WHO grade 
III is frequently characterized by recurrent genomic altera-
tions such as CDKN2A/CDKN2B locus loss on the p-arm of 
chromosome 9.110 Thus, cyclin-dependent kinase pathway 
inhibition might be a potential target to treat higher-grade 
meningiomas in the near future and needs to be explored 
in preclinical and clinical studies.
Potential Molecular Targets
A recent genomic screen of meningioma samples that lacked 
previously identified driver genes discovered recurrent 
mutations in POLR2A, a gene encoding for the DNA-directed 
RNA polymerase II subunit RPB1 in 6% of all cases. POLR2A 
mutations were exclusively detected in WHO grade I men-
ingiomas and were mainly associated with meningothe-
lial histology and a tendency to arise from the tuberculum 
sellae.14 The ubiquitin ligase tumor necrosis factor recep-
tor–associated factor 7 (TRAF7) is mutated in approximately 
20% of WHO grades I and II meningiomas.10,111 Mutations in 
the Krüppel-like factor 4 (KLF4) gene, a transcription factor, 
are exclusively seen in secretory meningiomas, which also 
harbor TRAF7 mutations.112 Unfortunately, there are no 
existing targeted agents that inhibit the underlying path-
ways of these alterations. Likewise, there are no tractable 
targeted agents that inhibit the activity of forkhead box 
M1 (FOXM1), a pro-mitotic transcription factor that may 
underlie the growth of some clinically aggressive meningi-
omas.102 As is the case with POLR2A, TRAF7, KLF4, FOXM1, 
and the molecular targets described below, additional pre-
clinical laboratory investigation is required before clinical 
trials targeting these molecules can be initiated.
Telomerase reverse transcriptase (TERT)-promoter 
mutations are associated with aggressive meningiomas113 
and a significantly shorter time to recurrence12 and were 
frequently observed in meningiomas with malignant 
histological progression.114 This mutation is associated 
with a significantly shorter overall survival compared with 
TERT-promoter wildtype grade III meningiomas (2.7 y vs 
10.8 y).115 Further validation of TERT mutations on overall 
survival in larger studies is needed in order to determine 
its diagnostic and prognostic role.
In rhabdoid meningiomas, a histological subtype of 
WHO grade III meningiomas, inactivation of the tumor sup-
pressor gene breast cancer 1 associated protein 1 (BAP1) 
was associated with an early tumor recurrence.116 Loss of 
immunohistochemical BAP1 expression is a surrogate for 
gene inactivation, and staining for BAP1 in this particular 
meningioma subtype might be a promising marker for 
risk assessment in these patients, as well as resolve true 
rhabdoid meningiomas from those which show histologic 
features of rhabdoid meningiomas but lack the mutation. 
Loss of BAP1 may confer sensitivity to EZH2 inhibition. 
Furthermore, SMARCE1 mutations were identified as a pre-
disposing factor for intracranial clear cell meningiomas as 
well as for spinal cord meningiomas.117,118 Taken together, 
these findings might contribute to a better stratification 
of meningioma patients in future clinical trials. After vali-
dating their prognostic role, molecular alterations such as 
TERT promoter and BAP1 mutations should be included in 
improved classification schemes to assign those patients 
to the most suitable treatment options. Moreover, taking 
molecular alterations into account might also facilitate the 
interpretation of results of clinical trials in the long term.
Fewer somatic targetable mutations have been identi-
fied in higher-grade meningiomas compared with grade 
I meningiomas. Higher-grade meningiomas do appear to 
harbor mutations that are predicted to be neoantigens, and 
therefore immunotherapy may play a larger role in higher-
grade tumors.119
Immunotherapy
Immunotherapy is also being investigated in meningioma 
patients. A  recent study examined immune infiltrates and 
found that expression of programmed death ligand 1 (PD-
L1) was increased in WHO grade III meningiomas.120,121 
Furthermore, higher numbers of PD-L1 expressing cells have 
been associated with a worse overall survival,120 and there 
is evidence that meningiomas contain antigen-experienced 
effector T cells of an exhausted phenotype.122 Given these 
data, an immunosuppressive microenvironment might 
contribute to the malignant phenotype of meningiomas.121 
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Consequently, phase II trials are currently investigating the 
efficacy of checkpoint inhibitors (nivolumab and pembroli-
zumab) in recurrent or residual high-grade meningiomas 
(NCT03279692, NCT02648997), and the combination of RT 
and checkpoint blockade may offer benefit to meningioma 
patients, as has been shown for other cancer types.123
Conclusions
For the majority of patients, surgery remains the first-line 
treatment for symptomatic and enlarging meningiomas. 
However, the lack of standardized outcomes for meningi-
oma patients in neurosurgical series makes comparisons 
and pooling of data challenging.4 EBRT and SRS tech-
niques have largely been used as a complementary thera-
peutic strategy in meningiomas, with excellent long-term 
local control. Brachytherapy is a salvage treatment option 
but is associated with high complication rates. Evidence 
supporting the current practices of RT in meningiomas is 
primarily from retrospective, single-institution reports, 
and studies of this nature have well-known weaknesses. 
RTOG 0539 and EORTC 22042 are two of the first coopera-
tive group studies evaluating the outcomes of adjuvant RT 
in higher-risk meningiomas, and the final results will be 
highly anticipated. Several systemic therapies for menin-
giomas remain under investigation. The use of trabectedin, 
a chemotherapeutic agent commonly used in sarcomas, is 
under evaluation in a randomized, multicenter phase II trial 
for patients with recurrent WHO grade II/III meningiomas 
(EORTC-1320-BTG). The use of AZD2014 (dual mTOR inhibi-
tor) is also currently under evaluation in 2 phase II trials 
in patients with recurrent WHO grades II and III meningi-
omas (NCT03071874) and in NF2 patients with progressive 
or symptomatic meningiomas (NCT02831257). A national 
Alliance-sponsored cooperative group phase II trial in the 
US is currently evaluating the efficacy of SMO, AKT1, and 
FAK inhibitors in patients with residual, recurrent, or pro-
gressive meningiomas with targetable alterations in SMO, 
AKT1, and NF2, respectively (NCT02523014/A071401). The 
results of these trials are highly anticipated, and the com-
munity awaits the results to establish the role of systemic 
therapies in treating patients with recurrent meningiomas.
Recommendations
Regarding treatment of patients with meningiomas and 
advancement of therapeutic research, the International 
Consortium on Meningiomas recommends:
• Patients should be made aware of all possible treatment 
options for primary and recurrent disease, including sur-
gical resection, radiation therapy, and clinical trials.
• Challenging cases and multiply recurrent cases should 
be reviewed with a multidisciplinary team to allow for 
consensus of optimal treatment approach.
• Development of a core outcome set that includes inter-
vention complication rates, epilepsy, cognitive func-
tion, and health-related quality of life will ensure that 
meningioma trials report outcomes that are relevant and 
important to both patients and clinicians.124,125
• Clinical trials should continue to stratify patients accord-
ing to relevant biological subtypes of meningiomas 
defined by mutational and epigenetic alterations.
• Rapid cycle translation from discovery and preclinical 
testing to clinical trials is needed to promote research on 
therapeutic advances in meningiomas.
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